What it all means
These observations are based on conversations with stakeholders from various Life Science companies across the Asia Pacific and as evidenced by transaction volumes per transaction type over the last two years alongside pipeline for 2026–2028.
on the ground
Combining market intel and pipeline data from CBRE clients, aggregated and anonymised.
Swipe or use the arrow keys to explore
APAC Life Sciences Insights
© 2026 CBRE, Inc.
What it all means on the ground
© 2026 CBRE, Inc.
APAC Life Sciences Insights
Head Offices
Continued footprint reduction, offset by quality upgrades in core markets
Return-to-office mandates remain strong across most APAC markets
Sales Offices
Strong increase in GCCs
GCC
Fewer rooftops, consolidated into larger regional coverage hubs
Al capability now anchors new mandates
Administrative side
Make side
Traditional
Flex Suite
Memberships
What it all means on the ground
© 2026 CBRE, Inc.
APAC Life Sciences Insights
Labs
Growth concentrated in incubation space hosted by larger corporates
Manufacturing
Networks decentralising closer to production and patient demand
Logistics
Steady increase across established APAC production hubs
Increase in the adoption of 3PL solutions
Administrative side
Make side
CDMO capacity expanding fastest as pharma outsources more